Hyperoside 是一种NF-κB抑制剂,从Hypericum monogynum中发现。Hyperoside 具有抗肿瘤、抗真菌、抗炎症、抗病毒和抗氧化的活性,并能诱导细胞凋亡。
生物活性 | Hyperoside is aNF-κBinhibitor, found fromHypericum monogynum. Hyperoside shows anti-tumor, antifungal, anti-inflammatory, anti-viral, and anti-oxidative activities, and can induceapoptosis[1][2]. |
体外研究 (In Vitro) | Hyperoside (12.5-100 μM; 6-24 h) inhibits MCF-7 and 4T1 cell growth[2]. Hyperoside (25-100 μM; 24 h) induces apoptosis of breast cancer cells[2]. Hyperoside inhibits the activation of the NF-κB signaling pathway via the attenuation of intracellular ROS generation[2].
Cell Viability Assay[2] Cell Line: | MCF-7 and 4T1 cells | Concentration: | 12.5, 25, 50, 75, or 100 μM | Incubation Time: | 6, 12, or 24 h | Result: | Inhibited cell growth in a time- and concentration-dependent manner. |
Apoptosis Analysis[2] Cell Line: | MCF-7 and 4T1 cells | Concentration: | 25, 50 and 100 μM | Incubation Time: | 24 h | Result: | Increased the expressions of Bax, cleaved caspase-3 and cleaved PARP, and decreased Bcl-2 in mRNA and protein levels. |
|
体内研究 (In Vivo) | Hyperoside (intraperitoneal injection; 50 mg/kg; every two day for 18 days) treatment inhibits breast tumor growth in vivo[1].
Animal Model: | Balb/c mice injected with 4T1 cells[2] | Dosage: | 50 mg/kg | Administration: | Intraperitoneal injection; 50 mg/kg; every two day for 18 days | Result: | Reduced the average tumor volume compared to the control group. Decreased Bcl-2 and increased bax and cleaved caspase-3. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Guttiferae
- Hypericum monogynumL.
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 125 mg/mL(269.18 mM;Need ultrasonic) 配制储备液 1 mM | 2.1534 mL | 10.7670 mL | 21.5341 mL | 5 mM | 0.4307 mL | 2.1534 mL | 4.3068 mL | 10 mM | 0.2153 mL | 1.0767 mL | 2.1534 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 50%PEG300 50% saline Solubility: 10 mg/mL (21.53 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.48 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (4.48 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.48 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|